Home > Insider Trading > Filing (0001209191-13-038809)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1383701	Conatus Pharmaceuticals Inc	CNAT	Pharmaceutical Preparations (2834)	203183915

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581748	U.a. Ii Healthcare Gilde Cooperative	Newtonlan 91 P.o. Box 85067 Utrecht P7 3508 AB		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-07-30	1,258,730	$0.00	1,258,730	No	4	C	Direct
Common Stock	Acquisiton	2013-07-30	46,675	$0.00	1,305,405	No	4	X	Direct
Common Stock	Disposition	2013-07-30	352	$11.00	1,305,053	No	4	S	Direct
Common Stock	Acquisiton	2013-07-30	16,742	$11.00	1,321,795	No	4	J	Direct
Common Stock	Acquisiton	2013-07-30	165,525	$11.00	1,487,320	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct
No	4	J	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-07-30	6,666,668	$0.00	808,080	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-30	3,717,861	$0.00	450,649	$0.00
Common Stock	Warrants to Purchase Shares of Series A Preferred Stock	Disposition	2013-07-30	385,070	$0.00	46,675	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct

Footnotes

The outstanding shares of Preferred Stock of the Issuer automatically converted into the shares of Common Stock of the Issuer at the closing of the Issuer's initial public offering (the "IPO") at a conversion ratio of 1 share of Common Stock for every 8.25 shares of Preferred Stock, rounded down to the nearest whole number, for no additional consideration.
Upon the conversion of all outstanding shares of Preferred Stock of the Issuer in connection with the closing of the IPO, the warrants to purchase shares of Series A Preferred Stock were converted to warrants to purchase Common Stock with an exercise price of $0.0825 per share, at a ratio of 1 share of Common Stock for every 8.25 shares of Preferred Stock, rounded down to the nearest whole number, and were then net exercised based on the IPO price of $11.00 per share.
The common stock was acquired upon conversion of a convertible promissory note exempt from the definition of a derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the IPO.